Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female subject \>= 18 years and =\<75 years.
Histologically or cytologically confirmed, locally advanced unresectable or metastatic breast cancer or gastric cancer.
ECOG score 0 or 1.
Life expectancy \>3 months.
According to the definition of RECIST1.1, the patient has at least one measurable lesion.
Adequate organ function prior to start treatment with KN026.
Able to understand, voluntarily participate and willing to sign the ICF.
Subjects (women of child-bearing potential and males with fertile female partner) must be willing to use viable contraception method.
You may not be if
Accepted any other anti-tumor drug therapies within 4 weeks before fist dose.
Accepted radiotherapy within 4 weeks before enrollment(Subjects are eligible, which accepted palliative therapies within 2 weeks before the first dose of KN026 for osseous metastatic and all the AEs recovered).
An anthracyclines antibiotic treatment, such as doxorubicin (Adriamycin) was received exceeding 300 mg/m² within 90 days before first KN026 dosing, or other equivalent dose antharcyclines.
Pregnant or nursing females；or intend pregnancy within this study period or within 6 monthes after the end of this study.
Has not recovered (ie, \>Grade 1) from AEs except alopecia and anemia.
History of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.
Severe chronic and active infection, need to system antibiosis/antiviral treatment.
Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage. -
Clareo Health | Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
